Literature DB >> 10561013

Treatment of aggressive non-Hodgkin's lymphoma.

B Coiffier1.   

Abstract

Clinically aggressive lymphomas are defined by the Revised European-American Classification for lymphoid neoplasms as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, and lymphoblastic lymphoma. Mantle cell lymphoma is atypical due to its indolent presentation and refractoriness to treatments. A review of current therapeutic possibilities for these different lymphomas is presented.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10561013

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  5 in total

Review 1.  Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy.

Authors:  Stephen M Beard; Lucy Wall; Louise Gaffney; Fiona Sampson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

3.  Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.

Authors:  Mitsuaki Tatsumi; Hiroyuki Sugahara; Ichiro Higuchi; Hiroki Fukunaga; Hironobu Nakamura; Yuzuru Kanakura; Jun Hatazawa
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

4.  ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.

Authors:  Sang Hyoung Park; Shin Kim; Ok Bae Ko; Ja Eun Koo; Danbi Lee; Yong Pil Jeong; Jooryung Huh; Sung-Bae Kim; Sang We Kim; Jae-Lyun Lee; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2006-09       Impact factor: 2.884

Review 5.  Genetic background and evolution of relapses in aggressive B-cell lymphomas.

Authors:  Darius Juskevicius; Stephan Dirnhofer; Alexandar Tzankov
Journal:  Haematologica       Date:  2017-05-29       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.